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To the Editor: Studies suggest that obsessive compulsive
disorder (OCD) is a prevalent disorder (7.8 - 31.7%) in patients
with schizophrenia and first-episode psychosis.1,2 Despite the
varied study designs that have been employed, calculated co-
morbidity rates support the conclusion that this co-morbidity is
not likely to be an incidental finding.2
However, there has been little study of co-morbid OCD in
non-Caucasian patients with schizophrenia-spectrum
disorders. Since it has been suggested that certain ethnic
groups (e.g. Asians) may have a lower prevalence of OCD,3 this
paper reports on the prevalence of co-morbid OCD in a group
of mixed-race male patients with either first-episode psychosis
or multiple-episode schizophrenia. This mixed-race group can
be traced back to Caucasian, Eastern and African origin and is
predominantly Afrikaans-speaking.4
Male patients were recruited from inpatient acute admission
units at Stikland Hospital (Bellville, Western Cape, South
Africa). The two groups (first-episode psychosis and multiple-
episode schizophrenia) were recruited independently of one
another and each group was assessed by a separate
interviewer. The studies were approved by the Ethics
Committee of the University of Stellenbosch and all subjects
provided written, informed consent.
The first group (N = 24) comprised first-episode psychosis
patients with a diagnosis of schizophrenia, schizoaffective
disorder or schizophreniform disorder. Patients were
diagnosed at baseline (before or within 4 weeks of initiation of
antipsychotic treatment) according to Diagnostic and Statistical
Manual-IV (DSM-IV) criteria5 using the Structured Clinical
Interview for DSM-IV (SCID-I)6 and if obsessive compulsive
symptoms (or OCD) were present, these were quantified by
means of the Yale-Brown Obsessive-Compulsive Checklist and
Severity Scale (Y-BOCS).7
Participants in the second group (N = 63) had a diagnosis of
schizophrenia and at least one previous admission for a
psychotic episode. Patients were diagnosed according to DSM-
IV criteria5 using the Diagnostic Interview for Genetic Studies
(DIGS version 2.0) 8 one week after admission.
The diagnosis of OCD was made using the relevant sections
of the DIGS or SCID-I. Both these assessment tools are
comprehensive clinical interviews designed for assessment of
anxiety, psychotic disorders, mood disorders and their
spectrum conditions. Ratings were performed by a psychiatrist
(PPO and LK). Prevalence rates were calculated using SPSS
10.0 for Windows.
The sample across the two groups comprised 87 men. The
first-episode group consisted of 20 men with a mean age of
29.4 (± 9.3) years and a duration of illness of 1 (± 2.07) years.
The multiple-episode psychosis group consisted of 63 men
with a mean age of 34.3 (± 8.6) years and a duration of illness
of 13.27 (± 9.1) years. The prevalence of OCD in the sample as a
whole was 1.1%. One patient (4.2%) in the first-episode group
(diagnosis of schizophrenia, treatment-naïve) and none in the
multiple-episode group fulfilled criteria for OCD.
Therefore, in this group of male patients of mixed ethnicity
with first-episode psychosis and multiple-episode
schizophrenia, the prevalence of co-morbid OCD was lower
than that previously reported in Caucasian samples. In
considering the first-episode group separately, the rate (4.2%) is
still in the lower range of reported values.1,2
A number of limitations are worth considering. First, as this
report focuses on male patients no conclusions can be drawn
about prevalence rates of OCD in this population of females of
mixed ethnicity. However, gender does not appear to impact
significantly on rates of OCD in schizophrenia and other
psychotic disorders since no consistent gender differences have
been reported in prevalence studies to date. 1,2 Second, although
structured clinical interviews were used, these (SCID-I, DIGS,
Y-BOCS) were not standardised across the groups. Moreover,
the Y-BOCS was administered to the first-episode psychosis
group only, which did not permit assessment of OC symptom
severity in the other group. Third, since this was a cross-
sectional interview historical information may have been
missed and the different symptom patterns waxing and
waning during the course of illness may have impacted on
these results. Fourth, assessment instruments (DIGS and 
SCID-I) were translated orally into Afrikaans during the
interviews. Formal translation and cross-cultural adaptation of
these instruments would have been preferable. Nevertheless,
the patients with co-morbid OCD displayed OCD symptom
patterns comparable to those documented in Caucasian and
black African patients.9,10
In conclusion, further studies using culturally adapted
instruments are needed. If low rates of OCD are replicated in
other studies of patients (of mixed ethnicity) with
schizophrenia, it may suggest that other factors, such as
cultural or genetic factors, have an important role to play.
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To the Editor: Cystic fibrosis (CF) is present in all South A f r i c a n
population groups.  In a significant proportion of patients a
diagnosis of CF can be confirmed by DNAanalysis and the
detection of two CF transmembrane conductance regulator (CFTR)
mutations, using the panels of mutations developed in this study.
The index of suspicion will also be raised in patients with a single
CFTR mutation.  DNAtesting is important, especially in re g i o n s
without access to reliable sweat tests, and should be considered an
aid to diagnosis.  In addition to receiving appropriate tre a t m e n t ,
patients and their families can receive more accurate genetic
counselling, CF carrier testing and prenatal diagnosis.
CF is one of the commonest autosomal recessive disord e r s
among white South Africans, with a prevalence of 1 in 2 000;
p revalence in the coloured population is 1 in 12 000.1 CF was
initially thought to be extremely rare in African blacks but a re c e n t
study showed a carrier frequency of 1 in 34 and a calculated
incidence of 1 in 4 624 births.2
CF is characterised by pancreatic insuff i c i e n c y, chro n i c
pulmonary disease, elevated sweat chloride levels and a number of
other features.  It can be difficult to diagnose because of the gre a t
variability of clinical presentation and severity.  The UK CF
Foundation Consensus Panel suggests confirmation of diagnosis
only after two positive sweat test results on separate occasions in a
patient with suggestive clinical feature s .3 H o w e v e r, as a diagnostic
test the sweat test is not ideal.  It re q u i res extreme technical rigour
by experienced staff using standardised methods.  In large parts of
South Africa such services are not readily available.
An alternative method of diagnosis became possible with the
cloning of the CFTR gene.4 CF is caused by mutations in the CFTR
gene — patients have two mutations and carriers have one.  Over
1 000 mutations have been identified.5 Patients may have two
identical mutations (homozygotes) or two diff e rent mutations
(compound heterozygotes), but the identification of two CF
mutations in a patient confirms the diagnosis of CF.
Given the number of CF-causing mutations and the
impracticality of screening the large CFTR gene, testing for
mutations that are common in a particular population makes
genetic testing useful as a diagnostic tool.  The aim of this study
was to improve the sensitivity and efficiency of diagnostic genetic
testing for CF in South Africa through the development of
customised panels of mutations for diff e rent South A f r i c a n
population groups.  Atotal of 201 white, 43 coloured and 14 black
CF patients with confirmed diagnoses were included in this pro j e c t
for CFTR mutation analysis.  
White and coloured patients were tested for 24 mutations
including ▲F508, 394delTT, Q493X, 3272-26A → G, 3120+1G→ A ,
R 117H, 3659delC, G542X, G551D, R553X, 621+1G → T, W1282X,
N1303K, 1717-1G → A, R1162X, R334W, 3849+10kbC → T, A 4 5 5 E ,
2 1 8 3 A A → G, 1078delT, ▲I507, R347P, S1251N, and E60X.  Five
c o l o u red patients in whom small amounts of DNA w e re available
f rom buccal scrapes were only tested for the ▲F508 mutation.
Black patients were initially tested for the 3120 +1G →A m u t a t i o n .
Those black patients whose mutations were still unidentified were
tested for the ▲F508 mutation.  Mutation detection assays have
been described pre v i o u s l y.6
Significant diff e rences in the CFTR mutation distribution were
found between groups, supporting the notion that population-
specific panels of mutations are re q u i red when using genetic tests
to diagnose CF (Table I).  Sixteen mutations were detected in the
South African white population, accounting for 91% of all CFTR
mutations in this population.   In the coloured population, the
▲F508 and 3120+1G→Amutations occur at appre c i a b l e
f requencies and account for 74.4 % (64/86) of mutations. In the
black population, 60.7% of mutations (17/28) were identified,
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